Effectiveness of topiramate in migraine prophylaxis, an observational study in a consecutive case-serie;Valoración de la efectividad del topiramato en el tratamiento preventivo de la migraña. Estudio observacional de una serie consecutiva de pacientes

Neurologia

Volumn 20, Issue 5, 2005, Pages 225-231

  Gracia Naya, Manuel ^a   Latorre Jimenez A ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Effectiveness; Headache; Migraine; Prevention; Topiramate

Indexed keywords

TOPIRAMATE;

ARTICLE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MIGRAINE; PARESTHESIA; PATIENT SATISFACTION; SIDE EFFECT; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS;

EID: 22144471946     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57.
2. Láinez JM, Vioque J, Hernández-Aguado I, Titus F. Prevalence of migraine in Spain. An assessment of the questionnaire's validity by clinical interview. En: Olesen J, editor. Headache classification and epidemiology. New York: Raven Press, 1994; p. 221-5.
3. Morgenstern LB, Huber JC, Luna-Gonzales H, Saldin HR, Grotta JC, et al. Headache in the emergency department. Headache 2001;41: 537-41.
4. Gracia-Naya M. Impacto y diferencias asistenciales de la migraña con o sin aura en las consultas de neurología. Neurologia 1999; 14:383-8.
5. Laml C, Buzath A, Yazdi K, Sandor PS. Ergot and triptan overuse in Austria-an evaluation of clinical data and cost. Cephalalgia 2002;22:807-11.
6. Gracia-Naya M, Latorre A, García de Pablo MS. Valoración de los pacientes con migraña enviados a una unidad de cefaleas. Neurología 2001;16:446-7.
7. Cull RE, Wells NEJ, Miocevich M. The economic cost of migraine. Br Med J 1992;2:103-15.
8. Láinez JM. Prevalencia de migraña laboral y su repercusión económica. Medicina del Trabajo 1995(Suppl. 1):9.
9. Solomon GD, Price KL. Burden of migraine: a review of its socioeconomic impact. Pharmacoeconomics 1997;11(Suppl. 1): 1-10.
10. Fishman P, Black L. Indirect costs of migraine in a managed care population. Cephalalgia 1999;19:50-7.
11. Fernandez-Concepción O, Canuet-Delis L. Discapacidad y calidad de vida en pacientes con migraña: factures determinantes. Rev Neurol 2003;36:1105-12.
12. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 2003;43: 14-8.
13. Ferrari A, Pasciullo G, Savino G, Cicero A, Ottani A, Bertolini A, et al. Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study. Cephalalgia 2004; 24:356-62.
14. Gracia-Naya M, Latorre-Jiménez AM. Diferencias entre los pacientes con migrana enviados a una unidad de cefaleas o a una consulta general de neurologia. Rev Neurol 2003;37:521-4.
15. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Pritsche G, Eikermann A, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004;62: 788-90.
16. Silberstein SD, Goadsby P. Migraine: preventive treatment. Cephalalgia 2002;22:491-512.
17. Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001;52:237-43.
18. Holroyd KA, Penzien DB, Condingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991;31:333-40.
19. Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 1984;4:91-6.
20. Forssman B, Lindblad CJ, Zhornikova V. Atenolol for migraine prophylaxis. Headache 1983;23:188-90.
21. Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Amer Osteopath Assoc 1984;84:343-7.
22. Ziegler DK, Hurwitz A, Preskom S, Hassanein R, Seim J. Propranolol and amitrptyline in prophylaxis of migraine. Arch Neurol 1993;50:825-30.
23. Diener HC, Matías-Guíu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced dosis: a comparison with propranolol 160 mg/daily. Cephalalgia 2002;22:209-21.
24. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992;19:340-5.
25. Reveiz-Herault L, Cardona AF, Ospina EG, Carrillo P. Eficacia de flunaricina en la profilaxisde Ia migraña: revisión metaanalítica de la bibliografía. Rev Neurol 2003;36:907-12.
26. Freitag FG, Collins S, Carlson H, Goldstein J, Saper J, Silberstein S, et al. Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-9.
27. Mathew NT, Saper IR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6.
28. Young WB, Hopkins MM, Shechter AL, Silberstein SD. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 2002; 22:659-63.
29. Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind placebo-controlled trials. CNS Spectr 2003;8:428-32.
30. Brandes JL Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al for the MIGR-002 Study Group. Topiramate for Migraine Prevention. A randomized Controlled Trial. JAMA 2004;291:965-73.
31. Silberstein SD, Neto W, Schmit J, Jacobs D. MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-5.
32. Diener HC, Tfet-Hansen P, Dahloff C, Láinez MJ, Sandrini G, Wang ShJ, et al. Topiramate in migraine prophylaxis. Results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50
33. Pascual J, Sánchez del Río M, Mateos V, Láinez JM, Hernández-Gallego J, Leira R, et al. Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. Neurología 2003;18:364-7.
34. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, et al. Guidelines for controlled trials of drugs in migraine. Cephalalgia 2000;20:765-86.
35. Martín R, Kuzniecky R, Ho S, Hetherungton H, Pan J, Sinclair K, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:321-7.
36. Jones MW. Topiramate-safety and tolerability. Can J Neurol Sci 1998;25:13-5.
37. Mathew NT, Kailasam J, Meadors L. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 2002;42:796-803.
38. Headache Classification Committee of International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8:1-96.
39. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996;47:871-5.